Definium Therapeutics, Inc. Common Shares Earnings Dividend
Earnings Summary
Net Profits | $-158.99Mn |
Definium Therapeutics, Inc. Common Shares’s net profit fell -271.95% since last year same period to $-158.99Mn in the Q2 2026. On a quarterly growth basis, Definium Therapeutics, Inc. Common Shares has generated -106.21% fall in its net profits since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Current Year | -0.55 |
Definium Therapeutics, Inc. Common Shares’s earning per share (EPS) estimates for the current quarter stand at -0.55 - a -12.24% fall from last quarter’s estimates.
Definium Therapeutics, Inc. Common Shares’s earning per share (EPS) estimates for the current year stand at -0.55.
Key Ratios
Earning Per Share (EPS) | -1.44 |
Definium Therapeutics, Inc. Common Shares’s earning per share (EPS) fell -188% since last year same period to -1.44 in the Q2 2026. This indicates that the Definium Therapeutics, Inc. Common Shares has generated -188% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-07 | -0.49 | -0.71 | -44.9% |
2026-08-06 | -0.55 | -1.44 | -161.82% |
